Predicting lung cancer recurrence from circulating tumour DNA. Commentary on 'Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution'.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Targeting MERTK and AXL inCancers · 2021
   Review
2. Mutation differences in circulating tumor DNAs from non-small cell lung cancer patients between Uygur and Han populations.Medicine · 2021
   Article
3. Clinical utility of tumor genomic profiling in patients with high plasma circulating tumor DNA burden or metabolically active tumors.Journal of hematology & oncology · 2018
   Article
4. Liquid Biopsy to Identify Actionable Genomic Alterations.American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting · 2018
   Review
5. Role of circulating tumor DNA in the management of early-stage lung cancer.Thoracic cancer · 2018
   Review

Corrections and comments

• Comment on
  Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution.2017

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as